Australia's PYC Therapeutics climbs to 1-month high on approval for human trials

PYC Therapeutics

10/02/2025 01:25

** Shares of PYC Therapeutics  PYC.AX  rise as much as 4.8%
to A$1.313, their highest levels since January 8
    ** The biotechnology co says it has received regulatory
approval to start human trials of its drug candidate, which
addresses an underlying cause of Polycystic Kidney Disease (PKD)
    ** PKD is a genetic disorder that causes the growth of
numerous cysts in the kidneys
    ** Stock has fallen 1.5% YTD, including current session's
moves
    

 (Reporting by Manasi Dasa Sundeep in Bengaluru)
 ((Manasi.DasaSundeep@thomsonreuters.com;))